Clinical trials: COPD (Chronic Obstructive Pulmonary Disease), open to volunteers
- Condition COPD (Chronic Obstructive Pulmonary Disease)
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Moderate to Severe COPD
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
- Trial name
- INDOS-B (NCT06531798)
- Testing
- Breztri Aerosphere
- Where
- 6 sites in India
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease), Chronic Bronchitis
Repeat Treatment With Metered Cryospray in Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
This study is being conducted to determine the safety of repeat metered cryospray (MCS) treatment in patients with COPD with chronic bronchitis previously treated with MCS.
- Trial name
- MCSRETREAT (NCT07468617)
- Testing
- Metered cryospray (MCS)
- Volunteers
- 10 people
- Sponsor
- CSA Medical, Inc.
COPD (Chronic Obstructive Pulmonary Disease)
COPD Exacerbation Follow Up
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Trial name
- NCT07118306
- Where
- 5 sites in United States
- Volunteers
- 485 people
- Sponsor
- Viz.ai, Inc.
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled…
- Trial name
- ENDURA-1 (NCT06959095)
- Testing
- Depemokimab
- Where
- 281 sites in United States, Argentina and 21 more
- Volunteers
- 981 people
- Sponsor
- GlaxoSmithKline
COPD, Emphysema
A Trial of the Implantable Artificial Bronchus 50 Flex in Patients With Severe Emphysema
A Study at Two Hospitals Testing the Safety and Effectiveness of the IAB 50 Flex, a New Implant for Adults with Severe COPD or Emphysema
- Trial name
- IAB-3 (NCT07086339)
- Testing
- Implantable pulmonary stent
- Where
- 2 sites in France, Netherlands
- Volunteers
- 20 people
- Sponsor
- Pulmair Medical, Inc.
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease
Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet
This study is a single-center, single-sequence, self-controlled, open design, aiming to investigate the effects of rifampicin and clarithromycin on the pharmacokinetics of RSS0343 in humans.
- Trial name
- NCT07696091
- Testing
- RSS0343 Tablet; Rifampicin Capsules, RSS0343 Tablet; Clarithromycin Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Reistone Biopharma Company Limited
Chronic Obstructive Pulmonary Disease (COPD)
Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT07355868
- Testing
- REGEND007
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
BPCO
Effectiveness of the Telemonitoring Program for Patients With Chronic Obstructive Pulmonary Disease (COPD)
Telemonitoring systems have already demonstrated their ability to improve clinical follow-up and reduce healthcare resource utilization in patients with chronic respiratory failure treated with non-invasive ventilation (NIV)…
- Trial name
- EProTele (NCT07697105)
- Testing
- Patients included in the intervention group will receive medical telemonitoring using the HCAlert medical device.
- Volunteers
- 340 people
- Sponsor
- Hope Care, S.A
Pulmonary Disease, Chronic Obstructive
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when…
- Trial name
- RENEW-COPD (NCT07759245)
- Testing
- Brenipatide, Standard of Care
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Cough, Asthma
Validation of the C-mo System - Cough Monitoring
The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.
- Conditions
- Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux
- Trial name
- C-mo_01 (NCT05989698)
- Testing
- C-mo System
- Where
- 8 sites in Portugal
- Volunteers
- 300 people
- Sponsor
- Cough Monitoring Medical Solutions
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- Trial name
- PRESTO (NCT07082738)
- Testing
- AZD6793
- Where
- 367 sites in United States, Argentina and 22 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD.
- Trial name
- Navigator (NCT07684820)
- Testing
- EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2
- Where
- 22 sites in United States
- Volunteers
- 600 people
- Sponsor
- Expedition Therapeutics, Inc
COPD, Emphysema or COPD
Utilising Hull Lung Health Study Data to Investigate the Performance of TidalSense Diagnostic Algorithms to Identify COPD and Pre-COPD Among Participants in the FRONTIER Programme.
Aim: To investigate the potential for N-Tidal to improve COPD diagnosis and enable detection of pre-COPD*. Objectives: 1. To assess the performance of TidalSense COPD Diagnostic Algorithms for COPD diagnosis in a real-world…
- Conditions
- COPD, Emphysema or COPD, Emphysema
- Trial name
- NCT06788613
- Volunteers
- 1,200 people
- Sponsor
- Chiesi UK
Bronchiectasis Adult, COPD
Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production
The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance.
- Trial name
- NCT06937216
- Testing
- Volara therapy
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Baxter Healthcare Corporation
Chronic Obstructive Pulmonary Disease (COPD)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce…
- Trial name
- MISSION (NCT07587658)
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Obstructive Pulmonary Disease, COPD
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.
- Trial name
- ROMEO (NCT07566195)
- Testing
- Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
- Where
- 13 sites in France
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with…
- Trial name
- ENDURA-2 (NCT06961214)
- Testing
- Depemokimab
- Where
- 193 sites in United States, Argentina and 14 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
MoblO2 to Maintain Oxygenation
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course.
- Trial name
- SSeifert (NCT07704567)
- Testing
- MoblO2 controls O2 flow, MoblO2 does not control flow
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Minnesota HealthSolutions
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive)…
- Trial name
- PERSEPHONE (NCT07190209)
- Testing
- Lunsekimig
- Where
- 314 sites in United States, Argentina and 23 more
- Volunteers
- 942 people
- Sponsor
- Sanofi